168 related articles for article (PubMed ID: 31345736)
21. [Not Available].
Fischli S; Henzen C
Ther Umsch; 2017; 74(8):433-439. PubMed ID: 29461151
[No Abstract] [Full Text] [Related]
22. Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio.
Kaneko M; Narukawa M
Ann Pharmacother; 2018 Jul; 52(7):632-638. PubMed ID: 29424239
[TBL] [Abstract][Full Text] [Related]
23. [Results of the LEADER study: current evidence and perspectives in research].
Mannucci E
G Ital Cardiol (Rome); 2016 Dec; 17(12 Suppl 2):28S-31. PubMed ID: 28151519
[TBL] [Abstract][Full Text] [Related]
24. An evaluation of liraglutide including its efficacy and safety for the treatment of obesity.
Lin CH; Shao L; Zhang YM; Tu YJ; Zhang Y; Tomlinson B; Chan P; Liu Z
Expert Opin Pharmacother; 2020 Feb; 21(3):275-285. PubMed ID: 31790314
[No Abstract] [Full Text] [Related]
25. [Cardiovascular effects of GLP-1 receptor agonist treatment: focus on liraglutide].
Haluzík M; Trachta P; Mráz M
Vnitr Lek; 2015; 61(7-8):635-40. PubMed ID: 26375689
[TBL] [Abstract][Full Text] [Related]
26. Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL.
Torekov SS
Cardiovasc Res; 2018 Aug; 114(10):e70-e71. PubMed ID: 30052921
[No Abstract] [Full Text] [Related]
27. GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?
Simó R; Hernández C
Diabetes; 2017 Jun; 66(6):1453-1460. PubMed ID: 28533296
[TBL] [Abstract][Full Text] [Related]
28. Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes.
Lambadiari V; Pavlidis G; Kousathana F; Varoudi M; Vlastos D; Maratou E; Georgiou D; Andreadou I; Parissis J; Triantafyllidi H; Lekakis J; Iliodromitis E; Dimitriadis G; Ikonomidis I
Cardiovasc Diabetol; 2018 Jan; 17(1):8. PubMed ID: 29310645
[TBL] [Abstract][Full Text] [Related]
29. Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients.
Madsbad S
Expert Rev Cardiovasc Ther; 2019 May; 17(5):377-387. PubMed ID: 31055989
[No Abstract] [Full Text] [Related]
30. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study.
Morano S; Romagnoli E; Filardi T; Nieddu L; Mandosi E; Fallarino M; Turinese I; Dagostino MP; Lenzi A; Carnevale V
Acta Diabetol; 2015 Aug; 52(4):727-32. PubMed ID: 25577244
[TBL] [Abstract][Full Text] [Related]
31. Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
Cheng L; Hu Y; Li YY; Cao X; Bai N; Lu TT; Li GQ; Li N; Wang AN; Mao XM
Diabetes Metab Res Rev; 2019 Oct; 35(7):e3168. PubMed ID: 30974033
[TBL] [Abstract][Full Text] [Related]
32. Cardiovascular safety and benefits of GLP-1 receptor agonists.
Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
[TBL] [Abstract][Full Text] [Related]
33. After 10 Years of Clinical Trials with Liraglutide in Diabetes, What do we Know About its Effects on Clinical Cardiovascular Outcomes?
Doggrell SA
Rev Recent Clin Trials; 2015; 10(1):68-77. PubMed ID: 25881636
[TBL] [Abstract][Full Text] [Related]
34. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis.
Barnett AH; Arnoldini S; Hunt B; Subramanian G; Hoxer CS
Diabetes Obes Metab; 2018 Aug; 20(8):1921-1927. PubMed ID: 29652101
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular Effects of Liraglutide.
Mikhail N
Curr Hypertens Rev; 2019; 15(1):64-69. PubMed ID: 29737256
[TBL] [Abstract][Full Text] [Related]
36. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.
Farr OM; Sofopoulos M; Tsoukas MA; Dincer F; Thakkar B; Sahin-Efe A; Filippaios A; Bowers J; Srnka A; Gavrieli A; Ko BJ; Liakou C; Kanyuch N; Tseleni-Balafouta S; Mantzoros CS
Diabetologia; 2016 May; 59(5):954-65. PubMed ID: 26831302
[TBL] [Abstract][Full Text] [Related]
37. Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States.
Johnston SS; Nguyen H; Cappell K; Nelson JK; Chu BC; Kalsekar I
J Med Econ; 2015; 18(9):666-77. PubMed ID: 25867133
[TBL] [Abstract][Full Text] [Related]
38. Prevalence and variations in gastric emptying delay in response to GLP-1 receptor agonist liraglutide.
Camilleri M; Carlson P; Dilmaghani S
Obesity (Silver Spring); 2024 Feb; 32(2):232-233. PubMed ID: 37927173
[No Abstract] [Full Text] [Related]
39. Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized, double-blind, placebo-controlled, crossover study.
Kumarathurai P; Anholm C; Fabricius-Bjerre A; Nielsen OW; Kristiansen O; Madsbad S; Haugaard SB; Sajadieh A
J Hypertens; 2017 May; 35(5):1070-1078. PubMed ID: 28129251
[TBL] [Abstract][Full Text] [Related]
40. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.
Østergaard L; Frandsen CS; Madsbad S
Expert Rev Clin Pharmacol; 2016; 9(2):241-65. PubMed ID: 26573176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
